7. Inhibición del Factor XIa con asundexian tras ictus isquémico no-cardioembólico (PACIFIC-Stroke), estudio fase 2.

Núria Claros Barrachina

Núria Claros Barrachina Medicina General y Neurología. Hospital General Universitario de Castellón

Palabras clave: Asundexian, Ictus

Abstract

Asundexian, un inhibidor del factor XIa, podría prevenir la trombosis sin aumentar el sangrado. El objetivo de este estudio es determinar la eficacia, definida por el hallazgo de nuevos ictus silentes detectados por resonancia magnética nuclear (RMN) o bien sintomáticos, y la seguridad, concretada como sangrado menor clínicamente relevante o sangrado mayor.

Asundexian, a factor XIa inhibitor, could prevent thrombosis without increasing bleeding. The objective of this study is to determine the efficacy, defined by incident MRI-detected covert brain infarcts or recurrent symptomatic ischaemic stroke. The safety outcome was major or clinically relevant non-major bleeding.

Citas

Vol. 379,3; págs 215-225. 2018. Johnston, S Claiborne et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. The New England journal of medicine. Doi: 10.1056/NEJMoa1800410

Vol. 76,12; págs 1466-1473. 2019. Pan, Yuesong et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA neurology. Doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704730/

Vol. 51,4; págs 1190-1198. 2020. Butcher, Ken S et al. Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke. Stroke. https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.027569

Vol. 12,6; págs 539-45. 2013. Whiteley, William N et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. The Lancet. Neurology. Doi: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(13)70079-6/fulltext

Vol. 78,6; págs 625-631. 2021. Hsu, Charles et al. Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. Journal of the American College of Cardiology. doi:https://www.sciencedirect.com/science/article/pii/S0735109721053213?via%3Dihub

Vol. 31,10. 2022. Sharma, Mukul et al. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. Doi: https://www.strokejournal.org/article/S1052-3057(22)00436-0/fulltext

Vol. 11,21; págs 6314. 26 Oct. 2022. Campello, Elena et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. Journal of clinical medicine. Doi: https://www.mdpi.com/2077-0383/11/21/6314

Vol. 81,8; págs 771-779. 2023. Harrington, Josephine et al. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. Journal of the American College of Cardiology. doi: 10.1016/j.jacc.2022.11.057